AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2176948 — intervention group
Group type: COMPARATOR
Intervention: Control (in vitro measurement without drug)
Number of subjects: 0
Study 2176948 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population correlation
Number of subjects: 0
Study 7443023 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive trials with ISI of 1 sec
Number of subjects: 24
Study 7443023 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive trials with ISI of 5 sec
Number of subjects: 24
Study 7443023 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive trials with ISI of 0.5-5.1 sec at random
Number of subjects: 24
Study 7443023 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive trials with no ISI (no stimulus pairing)
Number of subjects: 24
Study 28785110 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person shooting games
Number of subjects: 0
Study 28785110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus-dependent spatial strategies
Number of subjects: 0
Study 28785110 — intervention group
Group type: COMPARATOR
Intervention: 3D-platform games
Number of subjects: 0
Study 28785110 — intervention group
Group type: EXPERIMENTAL
Intervention: Action video game training
Number of subjects: 0
Study 27157961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 106
Study 27157961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 106
Study 25711329 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial elasticity measurement
Number of subjects: 0
Study 25711329 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical factors
Number of subjects: 0
Study 23581720 — intervention group
Group type: EXPERIMENTAL
Intervention: B-LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily, bismuth potassium citrate 220 mg b.i.d. for 14 days)
Number of subjects: 152
Study 23581720 — intervention group
Group type: COMPARATOR
Intervention: LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily for 14 days)
Number of subjects: 152
Study 23581720 — intervention group
Group type: EXPERIMENTAL
Intervention: B-LAL
Number of subjects: 152
Study 23581720 — intervention group
Group type: COMPARATOR
Intervention: LAL
Number of subjects: 152
Study 20581422 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of dialysis (when estimated GFR was 10.0 to 14.0 ml per minute)
Number of subjects: 828
Study 20581422 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of dialysis (when estimated GFR was 5.0 to 7.0 ml per minute)
Number of subjects: 828
Study 20581422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late initiation groups
Number of subjects: 828
Study 18430999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (10, 20, 40, or 60 IU)
Number of subjects: 92
Study 18430999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 92
Study 18430999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 17015418 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC-CPR
Number of subjects: 53
Study 15022653 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 42
Study 11061029 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 33
Study 11061029 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 33
Study 9420529 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day dietary recall (7DDR)
Number of subjects: 1278
Study 9420529 — intervention group
Group type: COMPARATOR
Intervention: 24-hour diet recall interview (24 HR)
Number of subjects: 1278
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo‐Flux dialyser
Number of subjects: 37
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtral dialyser
Number of subjects: 37
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: G120 M dialyser
Number of subjects: 37
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: CD 4000 dialyser
Number of subjects: 37
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: T 150 dialyser
Number of subjects: 37
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: F 60 dialyser
Number of subjects: 37
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: G10‐3N dialyser
Number of subjects: 37
Study 8272250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprammonium cellulose hollow‐fibre dialysis
Number of subjects: 37
Study 2961356 — intervention group
Group type: COMPARATOR
Intervention: Oral Cl2MDP (1600 mg twice daily for 16 weeks)
Number of subjects: 17
Study 2961356 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Cl2MDP (2.5 mg/kg on the first day and 5 mg/kg daily for up to 6 days)
Number of subjects: 17
Study 31690247 — intervention group
Group type: EXPERIMENTAL
Intervention: Online support group (OSG)
Number of subjects: 58
Study 29053231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) administered while experiencing nasal congestion (Cohort 1)
Number of subjects: 36
Study 29053231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) administered after treatment with oxymetazoline (Cohort 2)
Number of subjects: 36
Study 29053231 — intervention group
Group type: COMPARATOR
Intervention: Nasal glucagon (NG) administered with nasal congestion (Cohort 1)
Number of subjects: 36
Study 29053231 — intervention group
Group type: COMPARATOR
Intervention: Nasal glucagon (NG) administered after recovery from cold symptoms (Cohort 1)
Number of subjects: 36
Study 29053231 — intervention group
Group type: COMPARATOR
Intervention: Nasal glucagon (NG) administered with concomitant nasal decongestant (Cohort 2)
Number of subjects: 36
Study 27307465 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational meetings and peer support (n=646)
Number of subjects: 857
Study 27307465 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational meetings, peer support, and access to an outpatient clinic (n=646)
Number of subjects: 857
Study 27307465 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=211)
Number of subjects: 857
Study 24942096 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal sulcus approach
Number of subjects: 50
Study 24942096 — intervention group
Group type: COMPARATOR
Intervention: Intranasal approach
Number of subjects: 50
Study 22741255 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study 20507567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management
Number of subjects: 338
Study 20507567 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study 18524691 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session, therapist-administered CBT
Number of subjects: 75
Study 18524691 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session, patient-administered CBT
Number of subjects: 75
Study 18524691 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 75
Study 18524691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT versions
Number of subjects: 75
Study 15727582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG), a mixture of four probiotic strains, for 4 weeks
Number of subjects: 230
Study 15727582 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 230
Study 12046472 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson frame
Number of subjects: 80
Study 12046472 — intervention group
Group type: COMPARATOR
Intervention: genupectoral position
Number of subjects: 80
Study 9851273 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly i.m. injections for 12 months
Number of subjects: 174
Study 9851273 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 12 months
Number of subjects: 174
Study 7925800 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching movements (both fast and slow)
Number of subjects: 6
Study 2643296 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Number of subjects: 77
Study 2643296 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (90 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Number of subjects: 77
Study 2643296 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (90 mg/m2 by bolus every 3 weeks)
Number of subjects: 77
Study 766791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 5 mug/ml
Number of subjects: 2
Study 766791 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine plain
Number of subjects: 2
Study 766791 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with adrenaline 5 mug/ml
Number of subjects: 2
Study 766791 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 2
Study 6105336 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg PolyA.PolyU intravenously per week for 6 weeks
Number of subjects: 300
Study 6105336 — intervention group
Group type: COMPARATOR
Intervention: Normal saline intravenously on the same schedule
Number of subjects: 300
Study 30712716 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (4 capsules of 500 mg daily for 3 days)
Number of subjects: 70
Study 30712716 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (standard antimicrobial treatment)
Number of subjects: 70
Study 30712716 — intervention group
Group type: COMPARATOR
Intervention: Starch (placebo, 4 capsules daily for 3 days)
Number of subjects: 70
Study 29093283 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐NAC (surgery with N-acetylcysteine 600 mg)
Number of subjects: 30
Study 29093283 — intervention group
Group type: COMPARATOR
Intervention: S‐nonNAC (surgery only)
Number of subjects: 30
Study 29093283 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study 26208996 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 341
Study 26208996 — intervention group
Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 341
Study 23406981 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (1 g/day) for 12 months
Number of subjects: 347
Study 23406981 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 347
Study 21860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 156
Study 21860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 156
Study 21860040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 21860040 — intervention group
Group type: COMPARATOR
Intervention: Clinical Management (CM)
Number of subjects: 156
Study 19019899 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity aerobic exercise with heart rate feedback
Number of subjects: 48
Study 19019899 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity aerobic exercise without heart rate feedback
Number of subjects: 48
Study 19019899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed intensity aerobic exercise (50% of maximal heart rate reserve)
Number of subjects: 48
Study 19019899 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity aerobic exercise
Number of subjects: 48
Study 18427456 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (maximum dose 16 mg/day)
Number of subjects: 41
Study 18427456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 15449272 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic rectopexy
Number of subjects: 0
Study 15449272 — intervention group
Group type: COMPARATOR
Intervention: Open abdominal rectopexy
Number of subjects: 0
Study 11969062 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines (CAM)
Number of subjects: 496
Study 11969062 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicines with inhibitory effects on the coagulation cascade
Number of subjects: 496
Study 11969062 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicines affecting blood pressure
Number of subjects: 496
Study 11969062 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicines affecting cardiac function
Number of subjects: 496
Study 11969062 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicines causing sedation
Number of subjects: 496
Study 11969062 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicines with potential to alter electrolyte levels
Number of subjects: 496
Study 11969062 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbs recognized to interact with pharmaceuticals
Number of subjects: 496
Study 9831574 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic novel diet of milk only
Number of subjects: 45
Study 9831574 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk plus one designated food daily
Number of subjects: 45
Study 9831574 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3.4 MJ diet (control)
Number of subjects: 45
Study 7926247 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Number of subjects: 20
Study 7926247 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic PGF2-alpha
Number of subjects: 20
Study 2680178 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate cream twice daily
Number of subjects: 97
Study 2680178 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate cream once daily with base cream in the evening
Number of subjects: 97
Study 765293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine, 4 mg administered daily
Number of subjects: 70
Study 765293 — intervention group
Group type: COMPARATOR
Intervention: Naloxone, 500-2,000 mg administered on a contingent basis
Number of subjects: 70
Study 31981645 — intervention group
Group type: EXPERIMENTAL
Intervention: Omni Mode
Number of subjects: 0
Study 31981645 — intervention group
Group type: COMPARATOR
Intervention: Normal Mode
Number of subjects: 0
Study 30977392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation + standard early rehabilitation
Number of subjects: 42
Study 30977392 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation + standard early rehabilitation
Number of subjects: 42
Study 30977392 — intervention group
Group type: COMPARATOR
Intervention: Standard early rehabilitation-only
Number of subjects: 42
Study 27926647 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer analysis and online alerts (experimental arm)
Number of subjects: 7730
Study 27926647 — intervention group
Group type: COMPARATOR
Intervention: Visual analysis (control arm)
Number of subjects: 7730
Study 25996181 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive text messaging intervention
Number of subjects: 160
Study 23360810 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist used during handover
Number of subjects: 120
Study 23360810 — intervention group
Group type: COMPARATOR
Intervention: No checklist used during handover
Number of subjects: 120
Study 21303569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-fortified fruit juice (500 ml/d providing 18 mg Fe/d)
Number of subjects: 122
Study 21303569 — intervention group
Group type: COMPARATOR
Intervention: Placebo fruit juice (500 ml/d)
Number of subjects: 122
Study 19494532 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day) for 12 weeks
Number of subjects: 40
Study 19494532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) for 12 weeks
Number of subjects: 40
Study 19494532 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (maximum dose 20 mg/day) in a subset of patients (n = 9)
Number of subjects: 40
Study 19494532 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 23)
Number of subjects: 40
Study 17719288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 8335
Study 17719288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8335
Study 17719288 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (including ramipril)
Number of subjects: 8335
Study 15576217 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with palmaris longus interposition
Number of subjects: 183
Study 15576217 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition
Number of subjects: 183
Study 15576217 — intervention group
Group type: COMPARATOR
Intervention: Simple trapeziectomy
Number of subjects: 183
Study 15576217 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 183
Study 12508627 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy Short Course (DOTS)
Number of subjects: 0
Study 12508627 — intervention group
Group type: COMPARATOR
Intervention: Self Administered Therapy (SAT)
Number of subjects: 0
Study 9660578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg three times daily
Number of subjects: 28
Study 7861604 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex Spinal/Epidural set (P needles)
Number of subjects: 30
Study 7861604 — intervention group
Group type: COMPARATOR
Intervention: Hakko Disposable Needles set type H (H needles)
Number of subjects: 30
Study 2499169 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 18
Study 2499169 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 18
Study 2499169 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 18
Study 799567 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 20
Study 31564264 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional TAPP (T‐TAPP)
Number of subjects: 62
Study 31564264 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TAPP (M‐TAPP)
Number of subjects: 62
Study 27861261 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ventilation with a recruitment manoeuvre and 10 cmH2O of PEEP after surgery (group RM, n=20)
Number of subjects: 40
Study 27861261 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation with 6 cmH2O of positive end-expiratory pressure (PEEP; group C, n=20)
Number of subjects: 40
Study 26279206 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 26
Study 26279206 — intervention group
Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 26
Study 24026211 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1284
Study 24026211 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1284
Study 24026211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 1284
Study 24026211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1284
Study 21890882 — intervention group
Group type: EXPERIMENTAL
Intervention: AP Advance (APA)
Number of subjects: 0
Study 21890882 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 0
Study 21890882 — intervention group
Group type: COMPARATOR
Intervention: GlideScope Ranger
Number of subjects: 0
Study 19473611 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPA dialyzer
Number of subjects: 47
Study 19473611 — intervention group
Group type: EXPERIMENTAL
Intervention: PS dialyzer
Number of subjects: 47
Study 17950105 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (average dosage, 20.8 mg/d)
Number of subjects: 56
Study 17950105 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 56
Study 17950105 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 56
Study 17950105 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 56
Study 17950105 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Fenofibrate
Number of subjects: 56
Study 17950105 — intervention group
Group type: COMPARATOR
Intervention: FCHL patients compared to normolipemic controls
Number of subjects: 56
Study 15146262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 562
Study 15146262 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 562
Study 11330756 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual rehabilitation programme (group A)
Number of subjects: 239
Study 11330756 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 239
Study 9205766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg/d p.o. (Group A)
Number of subjects: 18
Study 9205766 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin 4 mg/kg/d p.o. in 3 divided doses (Group B)
Number of subjects: 18
Study 9205766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg/d p.o. plus Indometacin 4 mg/kg/d p.o. (Group C)
Number of subjects: 18
Study 8280546 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion 10 micrograms kg-1 h-1 (B10)
Number of subjects: 45
Study 8280546 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion 4 micrograms kg-1 h-1 (B4)
Number of subjects: 45
Study 8280546 — intervention group
Group type: COMPARATOR
Intervention: No background infusion (B0)
Number of subjects: 45
Study 3329963 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin + Aztreonam
Number of subjects: 62
Study 3329963 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin
Number of subjects: 62
Study 29104008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention emphasizing compliance, smoking cessation, exercise, inhaler use, and timely follow-up.
Number of subjects: 260
Study 29104008 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 260
Study 26771733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (bolus plus infusion) 12-48 hours prior to surgery (N=72 patients)
Number of subjects: 140
Study 26771733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline; N=68 patients)
Number of subjects: 140